| Business Summary | | SIGA
Technologies,
Inc.
is
a
development
stage
biotechnology
company.
Its
focus
is
on
the
discovery,
development
and
commercialization
of
vaccines,
antibiotics
and
novel
anti-infectives
for
serious
infectious
diseases.
Its
lead
vaccine
candidate
is
for
the
prevention
of
group
A
streptococcal
pharyngitis
or
"strep
throat."
The
Company
is
developing
a
technology
for
the
mucosal
delivery
of
its
vaccines
which
may
allow
those
vaccines
to
activate
the
immune
system
at
the
mucus
lined
surfaces
of
the
body
the
mouth,
the
nose,
the
lungs
and
the
gastrointestinal
and
urogenital
tracts
the
sites
of
entry
for
most
infectious
agents. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SIGA
Technologies,
Inc.
is
engaged
in
the
development
of
novel
vaccines
and
antibiotics
for
the
prevention
and
treatment
of
serious
infectious
diseases.
SIGA's
technology
platform
is
based
on
its
research
into
the
structure,
function
and
processing
of
bacterial
surface
proteins.
For
the
six
months
ended
6/30/01,
revenues
rose
from
$171
thousand
to
$987
thousand.
Net
loss
fell
71%
to
$888
thousand.
Results
reflect
higher
contracts
signed
and
lower
gross
margins. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Donald Drapkin Chairman | -- | Philip Sussman Pres,
CEO | -- | Thomas Konatich, 55 CFO
and Treasurer | $170K | Dennis Hruby, Ph.D., 49 CSO | 180K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|